The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective ...

Daiichi Sankyo has postponed its annual report by two weeks to allow for additional time to finalize the financial figures. | ...

With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...

In a brutal first quarter for Roche, key drugs in the company’s pharmaceutical division fall short of Wall Street ...

Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his personality ...

As pharma giants slash headcounts and routinely strike billion-dollar M&A deals, another trend is steadily playing out at many of the largest drugmakers: the adoption of AI on a corporate scale. Count ...

Normally on Big Pharma earnings calls, execs are eager to talk up their new launches and tout blockbuster expectations. | In ...

An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its ...

The FDA’s new practice of releasing redacted complete response letters (CRLs) in the name of “radical transparency” is ...